151 related articles for article (PubMed ID: 12428733)
1. L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice.
Reveron ME; Savelieva KV; Tillerson JL; McCormack AL; Di Monte DA; Miller GW
Neurotoxicology; 2002 Oct; 23(4-5):611-9. PubMed ID: 12428733
[TBL] [Abstract][Full Text] [Related]
2. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice.
Gainetdinov RR; Fumagalli F; Wang YM; Jones SR; Levey AI; Miller GW; Caron MG
J Neurochem; 1998 May; 70(5):1973-8. PubMed ID: 9572281
[TBL] [Abstract][Full Text] [Related]
3. Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice.
Kariya S; Takahashi N; Hirano M; Ueno S
J Mol Neurosci; 2005; 27(3):277-79. PubMed ID: 16280597
[TBL] [Abstract][Full Text] [Related]
4. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
[TBL] [Abstract][Full Text] [Related]
5. Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area.
Adelbrecht C; Agid Y; Raisman-Vozari R
Brain Res Mol Brain Res; 1996 Dec; 43(1-2):291-300. PubMed ID: 9037545
[TBL] [Abstract][Full Text] [Related]
6. Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models.
Ito Y; Fujita M; Shimada S; Watanabe Y; Okada T; Kusuoka H; Tohyama M; Nishimura T
Synapse; 1999 Mar; 31(3):178-85. PubMed ID: 10029235
[TBL] [Abstract][Full Text] [Related]
7. The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH(2)-MPTP).
Numis AL; Unger EL; Sheridan DL; Chisnell AC; Andrews AM
Mol Pharmacol; 2004 Sep; 66(3):718-27. PubMed ID: 15322265
[TBL] [Abstract][Full Text] [Related]
8. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA
J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter.
Jaber M; Dumartin B; Sagné C; Haycock JW; Roubert C; Giros B; Bloch B; Caron MG
Eur J Neurosci; 1999 Oct; 11(10):3499-511. PubMed ID: 10564358
[TBL] [Abstract][Full Text] [Related]
10. Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
Reksidler AB; Lima MM; Dombrowski PA; Barnabé GF; Andersen ML; Tufik S; Vital MA
J Neural Transm Suppl; 2009; (73):259-68. PubMed ID: 20411784
[TBL] [Abstract][Full Text] [Related]
11. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.
Takahashi N; Miner LL; Sora I; Ujike H; Revay RS; Kostic V; Jackson-Lewis V; Przedborski S; Uhl GR
Proc Natl Acad Sci U S A; 1997 Sep; 94(18):9938-43. PubMed ID: 9275230
[TBL] [Abstract][Full Text] [Related]
12. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
13. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis.
Larsen KE; Fon EA; Hastings TG; Edwards RH; Sulzer D
J Neurosci; 2002 Oct; 22(20):8951-60. PubMed ID: 12388602
[TBL] [Abstract][Full Text] [Related]
14. Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
Joyce JN; Der TC; Renish L; Osredkar T; Hagner D; Reploge M; Sakakibara S; Ueda S
Exp Neurol; 2004 May; 187(1):178-89. PubMed ID: 15081599
[TBL] [Abstract][Full Text] [Related]
15. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
[TBL] [Abstract][Full Text] [Related]
16. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure.
Harvey DC; Laćan G; Melegan WP
Exp Brain Res; 2000 Aug; 133(3):349-58. PubMed ID: 10958525
[TBL] [Abstract][Full Text] [Related]
17. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.
Fumagalli F; Gainetdinov RR; Wang YM; Valenzano KJ; Miller GW; Caron MG
J Neurosci; 1999 Apr; 19(7):2424-31. PubMed ID: 10087057
[TBL] [Abstract][Full Text] [Related]
18. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Kemmerer ES; Desmond TJ; Albin RL; Kilbourn MR; Frey KA
Exp Neurol; 2003 Sep; 183(1):81-6. PubMed ID: 12957491
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
Staal RG; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000
[TBL] [Abstract][Full Text] [Related]
20. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
